A clinical trial involving liraglutide began recruiting as of November 6, 2026. The study, registered as NCT07901777, is titled "Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity." According to its listing, the trial's current status is recruiting. No phase designation was provided for this study. The trial aims to examine weight loss outcomes over a two-year period, comparing GLP-1 medications, which include liraglutide, against sleeve gastrectomy in adults with obesity. No results have been posted at this stage, and the event data does not include any outcome information. Liraglutide remains an approved medication. This update reflects only the trial's recruitment status and design as registered, and does not indicate any findings regarding effectiveness or safety of either intervention. Readers interested in the background of liraglutide, including its approved uses and regulatory history, can consult the compound overview for additional context.
Trial Comparing Liraglutide to Sleeve Gastrectomy Now Recruiting
See the full liraglutide overview
Source: https://clinicaltrials.gov/study/NCT07901777